Skip to content
GradedGrading live · 2026
LongevityGraded
Menu

Graded review

InsideTracker Review: Worth It in 2026?

InsideTracker adds DNA and an 'InnerAge' score to blood panels. The core markers are real, but it's pricier per marker and recommendations skew to upsells.

Researched & graded by Tom Vance · Lead Reviews Analyst
Last graded
Evidence scorecard
A

Top of the scorecard

Grade A

CoreAge Rx

Doctor-reviewed longevity peptides and NAD+ with one published per-protocol price and built-in human support.

$93–$99/mo (12-mo plan)

Check availability
Pricing
Flat monthly, no membership
Pharmacy
503A compounding pharmacy
Labs
No labs required
Consult
Clinician review included
Support
1:1 nurse + dietitian

Advertising disclosure — we may earn a commission at no extra cost to you. Affiliate partners are listed first on the scorecard.

C

Also on the scorecard

Grade C

Try Ageless

Every advertised longevity price is an intro-code rate, and the site says outright the real figure arrives after review.

$176–$249/mo list

Visit Try Ageless

Every advertised longevity price is a limited-time intro-code rate: the real list prices are $249 (NAD+ injection) and $176 (sermorelin injection), not the $199 and $126 shown. Compounded and not FDA-approved. Graded on the same rubric as every other provider on our scorecard.

The one-sentence version

InsideTracker is a legitimate DTC blood-test platform whose underlying science is real where it overlaps the cheap, outcome-validated markers that matter — but its distinctive features (a one-time DNA layer, an algorithmic "InnerAge" number, and personalized food/supplement recommendations) are where the honest cautions live. You pay more per marker than the broad-panel competition, the InnerAge score is a proprietary composite that isn't a validated bio-age clock, and the recommendation engine skews toward supplements and add-ons — a structural conflict when the company benefits from your acting on its nudges. Worth it for a specific buyer; oversold to everyone else. For where lab-membership testing sits in the field, see our pillar on longevity medicine: what's proven vs hyped, and for the broader head-to-head, our best longevity blood test services roundup.

What you actually get

InsideTracker is a direct-to-consumer blood-analytics service. You buy a panel (tiers run from a small focused set up to a ~43-marker "Ultimate" plan, with annual subscriptions stacking multiple retests across the year), optionally add a one-time DNA kit, and get results on a dashboard that flags markers against "optimized" zones, generates an InnerAge estimate, and produces personalized nutrition, exercise, and supplement recommendations. Pricing is current-2026 market info and shifts, but the shape is consistent: the per-test and annual plans land at a premium relative to broad "100+ marker" memberships, and the value proposition is integration and guidance, not raw marker count.

What you do not get is treatment. Like most of the category, InsideTracker is a measurement-and-recommendation product: it surfaces numbers and suggests actions, but it isn't a clinic titrating a statin or managing a condition. That test-but-don't-treat structure is the defining catch of the whole DTC lab band, which we map in longevity clinics vs lab memberships.

At a glance

InsideTracker
What it isDTC blood analytics + optional DNA + recommendations
PanelsUp to ~43-marker 'Ultimate'; annual plans stack retests
PricePremium per marker vs broad panels (current market info)
Useful coreApoB, hs-CRP, HbA1c; ferritin/vitamin D/thyroid catches
InnerAgeProprietary blood composite — NOT a validated clock
Treats results?No — surfaces, scores, and recommends; doesn't treat
A polished, legitimate product whose distinctive features — DNA, InnerAge, personalization — are exactly where the honest cautions sit. Pricing is current-2026 market info.

The good: the outcome-validated core is in there

Where InsideTracker overlaps the markers with genuine hard-outcome evidence, it's doing something useful — these are the numbers a standard physical often skips:

  • ApoB / lipid particles. ApoB counts every atherogenic particle, so when it disagrees with LDL-C (common in metabolic syndrome and diabetes) it's the better predictor of cardiovascular events1. A panel that surfaces it is an upgrade over a basic lipid screen.
  • hs-CRP. Low-grade inflammation that predicted first cardiovascular events at least as well as LDL cholesterol in a large prospective study2. (Non-specific — recheck a high reading when well.)
  • HbA1c / glucose. HbA1c predicted all-cause and cardiovascular mortality continuously in a population study, with risk rising across the range3 — genuinely worth tracking.
  • Ferritin, vitamin D, thyroid markers. Not longevity magic, but catching a treatable deficiency people misattribute to "aging" is real value.

If InsideTracker gets a motivated person these numbers and they act on them with a clinician, it has earned a slice of its fee. That's the legitimate core — and it's the same core every good panel shares.

The catches: per-marker price, the InnerAge number, and supplement nudges

Now the honest case against the framing — three things specific to InsideTracker.

1. You pay more per marker. InsideTracker's panels are priced at a premium relative to the broad-panel memberships, and the marker counts are often smaller. You're paying for the DNA integration and the recommendation layer, not for a longer list. If your goal is simply getting the cheap outcome-validated core in front of a clinician, a broad-panel competitor often does it for less — we lay out the price-vs-padding trade across services in our best longevity blood test services roundup.

2. "InnerAge" is a proprietary composite, not a validated clock. InnerAge derives an "inner age" from a subset of your blood markers via the company's own algorithm. That can be a reasonable motivational framing of your metabolic numbers, but it is not a validated DNA-methylation epigenetic clock, and it isn't validated as a target proven that lowering it extends your life. Don't confuse it with the bio-age tests we grade in biological age tests — and if a bio-age readout is what you actually want, see the best at-home biological-age test. Treat InnerAge as a repackaging of your blood markers, not a separate measurement of how fast you're aging.

3. The recommendations skew toward products. The personalization engine is the selling point and the structural conflict at once. Nutrition and exercise suggestions are mostly harmless and sometimes helpful, but the supplement recommendations are where to keep your skepticism up — because the incentive to make a panel feel like it found something you should buy is baked into the category. Two examples of why marker-chasing misleads, both featured on long panels:

  • IGF-1 is marketed as a youth hormone, but its mortality relationship is U-shaped — both low and high IGF-1 associate with higher mortality in meta-analysis4. "Optimize your IGF-1 upward" is biologically naïve.
  • Homocysteine looks treatable, but large randomized trials that lowered it with folic acid and B vitamins did not reduce cardiovascular events5. Buying a B-supplement to push it down is buying a passenger, not fixing a driver.

When a dashboard flags these against tight "optimized" zones and pairs the flag with a supplement suggestion, read it against standard clinical thresholds — not the color coding.

The verdict

Grade: C+ — good science, premium price, upsell skew

  • The outcome-validated core (ApoB, hs-CRP, HbA1c) is real value and the dashboard is polished.
  • You pay more per marker than broad-panel rivals — price-focused buyers do better elsewhere.
  • InnerAge is a proprietary blood-marker composite, not a validated epigenetic clock or a target proven to extend life.
  • Supplement recommendations carry a built-in conflict; IGF-1 (U-shaped mortality) and homocysteine (lowering failed in HOPE-2) mislead as targets.
  • Most decisively, it tests but doesn't treat — surfacing a flag isn't moving an outcome.
Two axes kept separate: the small actionable core (real) versus the DNA-plus-InnerAge-plus-personalization premium (oversold).

The grade, and how we got there

Two axes, kept separate because conflating them is the trap:

  • As a way to surface outcome-validated markers and present them well: moderate-to-good. ApoB, hs-CRP, HbA1c, and a deficiency catch are real value, and the dashboard is polished.
  • As a "DNA + InnerAge + personalization" health upgrade worth the premium: weaker. You pay more per marker, InnerAge is a proprietary repackaging rather than a validated clock, and the recommendations lean toward products the company benefits from. And — decisively — it tests without treating.

That lands the letter grade in the middle, dragged down a half-step from the broad-panel baseline by the per-marker premium and the upsell skew: a C+. Reasonable for someone who specifically values the DNA-plus-blood integration and will treat the supplement recommendations with healthy skepticism; a poorer deal for someone who just wants the cheap actionable core, which a broad panel delivers for less. The two biggest longevity levers in all of epidemiology aren't on any InsideTracker panel anyway — cardiorespiratory fitness, among the most powerful survival predictors ever measured6, and grip strength, which outpredicted blood pressure across 17 countries in the PURE study7.

Who should and shouldn't buy it

  • Reasonable buyer: someone who specifically wants DNA-informed blood guidance, will act on abnormal results with a clinician, and can ignore supplement nudges that aren't outcome-backed.
  • Poor fit: anyone whose goal is simply getting ApoB, Lp(a), hs-CRP, and HbA1c at the lowest price (a broad panel wins), or who'll treat InnerAge as a real bio-age score or the supplement list as a prescription.

Bottom line

InsideTracker's real value is the same as any good panel's — surfacing the cheap, outcome-validated markers (ApoB, hs-CRP, HbA1c) your checkup skips, presented on a polished dashboard. Its distinctive features are where the cautions live: you pay more per marker than broad-panel rivals, InnerAge is a proprietary composite rather than a validated epigenetic clock, and the recommendation engine skews toward supplements the company benefits from. Most important, it tests without treating. Worth it for a buyer who values DNA-plus-blood integration and keeps the upsell at arm's length; a poorer deal for anyone who just wants the actionable core cheaply. To compare it head-to-head against Function, Lifeforce, and Superpower, see our best longevity blood test services roundup; for an independently graded look at the labs and clinics selling these memberships, see our longevity clinic rankings.

Frequently asked questions

Is InsideTracker worth it?

It depends who you are. For someone who specifically values DNA-informed blood guidance and will act on abnormal results with a clinician — while ignoring supplement nudges that aren't outcome-backed — it can be reasonable. For someone who just wants the cheap, outcome-validated core (ApoB, Lp(a), hs-CRP, HbA1c) at the lowest price, a broad-panel membership usually delivers it for less. You're paying InsideTracker a premium for DNA integration and a recommendation layer, not for a longer marker list.

Is the InsideTracker InnerAge score accurate?

InnerAge is a proprietary composite the company derives from a subset of your blood markers — it's a motivational repackaging of those numbers, not a validated DNA-methylation epigenetic clock, and it isn't validated as a target proven that lowering it extends your life. Treat it as a presentation of your metabolic markers, not as a separate measurement of how fast you're aging. If a biological-age readout is what you want, that's a different product with its own limits.

How is InsideTracker different from Function Health?

Both are test-but-don't-treat DTC platforms surfacing the same outcome-validated core. The differences: InsideTracker layers a one-time DNA kit and an InnerAge score onto smaller blood panels and leans on personalized supplement recommendations, while Function emphasizes a broad '100+ biomarker' panel. InsideTracker tends to cost more per marker. Neither treats your results — acting on an abnormal number falls to you and your clinician.

Should I follow InsideTracker's supplement recommendations?

Be selective. Nutrition and exercise suggestions are mostly low-risk, but the supplement recommendations carry a built-in conflict, and marker-chasing can mislead — IGF-1 has a U-shaped mortality curve (higher isn't better) and homocysteine lowering with B-vitamins failed to cut cardiovascular events in large trials. Read flagged markers against standard clinical thresholds rather than tight 'optimized' zones, and take anything actionable to a clinician before buying supplements off a dashboard.

References

  1. Glavinovic T, Thanassoulis G, de Graaf J, et al. (2022). Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association. https://pubmed.ncbi.nlm.nih.gov/36216435/
  2. Ridker PM, Rifai N, Rose L, et al. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/12432042/
  3. Khaw KT, Wareham N, Luben R, et al. (2001). Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. https://pubmed.ncbi.nlm.nih.gov/11141143/
  4. Burgers AM, Biermasz NR, Schoones JW, et al. (2011). Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/21795450/
  5. Lonn E, Yusuf S, Arnold MJ, et al. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE-2). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/16531613/
  6. Mandsager K, Harb S, Cremer P, et al. (2018). Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Network Open. https://pubmed.ncbi.nlm.nih.gov/30646252/
  7. Leong DP, Teo KK, Rangarajan S, et al. (2015). Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. https://pubmed.ncbi.nlm.nih.gov/25982160/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.